Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 3, 1996, Pages 1014-1017

  Cundy, Tim ^a,b   Farquhar, Cynthia M ^a   Cornish, Jillian ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE;

ADULT; AMENORRHEA; ARTICLE; BONE ATROPHY; BONE DENSITY; CLINICAL ARTICLE; DRUG EFFECT; DRUG MEGADOSE; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; FEMALE; HORMONAL THERAPY; HUMAN; HYPOGONADISM; PREMENOPAUSE; PRIORITY JOURNAL; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; BODY WEIGHT; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; FEMUR NECK; HUMANS; LUMBOSACRAL REGION; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PREMENOPAUSE; SPINE; TIME FACTORS;

EID: 0029862751     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.3.1014     Document Type: Article

References (26)

1. Riis BJ, Christiansen C, Johansen JS, Jacobson J. 1990 Is it possible to prevent bone loss in young women treated with lutenizing hormone-releasing hormone agonists? J Clin Endocrinol Metab. 70:920-924.
2. Eldred JM, Haynes PJ, Thomas EJ. 1992 A randomized double-blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clin Endocrinol (Oxf). 37:354-359.
3. Horowitz M, Wishart JM, Need AG, Morris HA, Nordin BEC. 1993 Effects of norethisterone on bone related biochemical variables and forearm bone mineral in postmenopausal osteoporosis. Clin Endocrinol (Oxf). 39:649-655.
4. Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC. 1994 Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med. 96:521-530.
5. Gallagher JC, Kabel WT, Goldgar D. 1991 Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 90:171-178.
6. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. 1991 Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br Med J. 303:13-16 (correction. 303:202).
7. Hellberg D, Claesson B, Nilsson S. 1991 Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynecol Obstet. 34:243-248.
8. Farquhar CM, Rogers V, Franks S, Pearce S, Wadsworth J, Beard RW. 1989 A randomised controlled trial of medroxyprogesterone acetate and psychotherapy for the treatment of pelvic congestion. Br J Obstet Gynaecol. 96:1153-1162.
9. Luciano AA, Turksey RN, Carleo JL. 1988 Evaluation of oral MPA in the treatment of endometriosis. Obstet Gynecol. 72:323-326.
10. Ortiz A, Hiroi F, Starczyk FZ, Goebelsman V, Mishell DR. 1977 Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo MPA. J Clin Endocrinol Metab. 44: 32-38.
11. Jeppsson S, Johansson EDB, Ljundberg O, Sjoberg N. 1977 Endometrial histology, and circulatory levels of MPA, estradiol, FSH and LH in women with MPA-induced amenorrhoea compared to women with secondary amenorrhoea. Acta Obstet Gynecol Scand. 56:43-48.
12. Nordin BEC, Need AG, Bridges A, Horowitz M. 1992 Relative contributions of years since menopause, age and weight to vertebral density in postmenopausal women. J Clin Endocrinol Metab. 74:20-23.
13. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. 1994 Recovery of bone density in women who stop using medroxyprogesterone acetate. Br Med J. 308:247-248.
14. Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. 1992 Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 75:692-697.
15. Marcus R, Cann C, Madvig P, et al. 1985 Menstrual function and bone mass in elite women distance runners: endocrine and metabolic features. Ann Intern Med. 102:158-163.
16. Biller BMK, Coughlin JF, Saxe V, Shoenfeld D, Spratt DI, Klibanski A. 1991 Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol. 78:996-1001.
17. Herzog W, Minne H, Deter C, et al. 1993 Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission. J Bone Miner Res. 8:597-605.
18. Matta WH, Shaw RW, Hesp R, et al. 1988 Reversible trabecular bone density loss following induced hypoestrogenism with the GnRH analogue buserilin in premenopausal women. Clin Endocrinol (Oxf). 29:45-51.
19. Klibanski A, Greenspan SL. 1986 Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med. 315:542-546.
20. Prior JC, Vigna YM, Schechter MT, Burgess AE. 1990 Spinal bone loss and ovulatory disturbances. N Engl J Med. 323:1221-1227.
21. Grey A, Cundy T, Reid I. 1996 Medroxyprogesterone enhances the spinal bone density response to oestrogen in postmenopausal women. Clin Endocrinol (Oxf). In press.
22. Siminoski K, Goss P, Drucker DJ. 1989 The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med. 111:758-760.
23. Green EO, Weinshelbaum A, Simmons R. 1990 Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int. 46:294-299.
24. Leiman G. 1972 Depot medroxyprogesterone acetate as a contraceptive agent-effect on weight and blood pressure. Am J Obstet Gynecol. 114:97-102.
25. Lindsay R, Cosman F, Herrington BS, Himmelstein S. 1992 Bone mass and body composition in normal women. J Bone Miner Res. 7:55-63.
26. Lindsay R, Hart DM, Forrest C, Baird C. 1980 Prevention of spinal osteoporosis in oophorectomised women. Lancet. 2:1151-1153.